Navigation Links
YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
Date:2/13/2009

.3 million for the first six months of fiscal 2009 compared with $4.1 million for the first six months of fiscal 2008.

Licensing and product development expenses were $4.4 million for the second quarter of fiscal 2009 compared with $4.2 million for the second quarter of fiscal 2008. Licensing and product development expenses were $8.3 million for the first six months of fiscal 2009 compared with $7.8 million for the first six months of fiscal 2008.

Costs associated with development activities for nimotuzumab increased by $1.2 million to $2.2 million and by $1.3 million to $3.3 million for the three and six months ended December 31, 2008 respectively, compared to the same periods in the prior year. The increase in expenses is related to preparation for the two new clinical trials and final payments for the trial in colorectal cancer.

Costs associated with development activities for AeroLEF(TM) decreased by $0.2 million to $0.6 million for the three month period ended December 31, 2008 compared to the same period in the prior year. For the six month period ended December 31, 2008 costs were $1.1 million, similar to the same period in the prior year.

Net loss for the second quarter of fiscal 2009 was $3.2 million ($0.06 per share) compared to $4.5 million ($0.08 per share) for the same period last year. Net loss for the first six months of fiscal 2009 was $6.3 million ($0.11 per share) compared to $8.1 million ($0.15 per share) for the same period last year.

As at December 31, 2008 the Company had cash and cash equivalents and short-term deposits totaling $50.1 million and payables and accrued liabilities totaling $2.1 million compared to $58.1 million and $2.0 million respectively at June 30, 2008.

As at December 31, 2008 the Company had 58,216,309 common shares outstanding, of which 2,380,953 common shares are held in escrow to be released contingent upon the completion of certain milestones.

About YM B
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
2. Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
3. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results
5. BD Biosciences to Distribute FCS Express
6. MichBio Will Publish 2009 Michigan Biosciences Directory and Resource Guide
7. Cell Biosciences Introduces Kits for Oncoprotein Analysis
8. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
9. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
10. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
11. Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014 PMG Research, Inc. ... Research is a network of sites that provide clinical research ... 2 million patient lives through its partnerships with large physician ... 11 hub site locations in the Southeastern United States and ... of the board will be held by: Dr. ...
(Date:11/26/2014)... Continuing its award-winning streak, Nerium International, the ... Awards for outstanding creative achievement by its marketing and ... the organization’s top honor, in the Branding category for ... April of this year. The event showcased top speakers ... was awarded a Gold MarCom Award in the Special ...
(Date:11/26/2014)... 26, 2014 SoundConnect , an ... proud to announce that Darren Suders has joined the ... Darren will drive the partner program through ... , Darren brings more than 10-years of ... roles in channel operations, from policy development, to partner ...
(Date:11/26/2014)... -- Bio-Techne Corporation (NASDAQ: TECH ) announced ... to serve in a newly created position of Senior ... will be responsible for managing the operations of Bio-Techne,s ... acquired in July 2014 and the recently acquired CyVek ... -based ProteinSimple develops and commercializes proprietary systems and consumables ...
Breaking Biology Technology:PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2SoundConnect Appoints Director of Channel Development & Sales 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3
... be participating in the Barclays Capital 2010 Global Healthcare Conference in Miami, Fla. , on March 23, 2010 , at 8:30 a.m. Eastern Time .   , ... , ... ... ...
... for life science researchers, has selected Biodiagnostics as its new distributor of IPA® in Greece , Turkey ... systems at the core of life science research. , ... ... ...
... patient cases using magnetic resonance-guided heat (laser interstitial ... cancer recurrence after surgical removal of the prostate ... of Interventional Radiology,s 35th Annual Scientific Meeting in ... salvage radiation treatment and are often presented with ...
Cached Biology Technology:Zimmer Holdings to Present at Barclays Capital 2010 Global Healthcare Conference 2Ingenuity Systems Announces New Distributor for Greece, Turkey and the Balkans 2Ingenuity Systems Announces New Distributor for Greece, Turkey and the Balkans 3The hot -- and cold -- interventional radiology treatments for recurrent prostate cancer 2The hot -- and cold -- interventional radiology treatments for recurrent prostate cancer 3
(Date:11/10/2014)... U.S. store shelves in early 2010, and people have ... packets can be tossed into a washing machine without ... The convenience, though, has come with risks for young ... Children,s Hospital found that from 2012 through 2013, U.S. ... than 6 years of age swallowing, inhaling, or otherwise ...
(Date:11/7/2014)... 2014  In conjunction with the Glendale ... Community Foundation of the Verdugos has announced the " ... a $250,000 initiative to keep the Verdugo Regional Crime Lab ... six months of existence, the Lab has processed more than ... law enforcement. "Because our number one priority is ...
(Date:11/6/2014)... a team of Florida State University biologists could lead ... to and survive environmental swings such as droughts or ... of the journal The Plant Cell , sheds ... proteins) is organized in a cell and how plants ... on and others are turned off. , "If you ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Maize analysis yields whole new world of genetic science 2
... to study addicted,smokers, a new drug that attaches ... implicated in nicotine addiction ,may help studies ... and schizophrenia.,Developed by UC Irvine Transdisciplinary Tobacco Use ... selective binding agent,that identifies specific areas of the ...
... may be precipitated by a "traffic jam" within neurons ... and structures in the cells, according to new studies ... models of Alzheimer's disease and in human brain samples ... breakdown in neurons that appears to prevent the normal ...
... Scientists at Joslin Diabetes Center have discovered one reason why ... developing type 2 diabetes later in life. In studies of ... pancreas's ability to later secrete enough insulin in response to ... don't have delivery of enough nutrients from the mother to ...
Cached Biology News:Drug That 'Tags' Decision-making Areas Of The Brain May Aid 2Neuronal 'traffic jam' marks early Alzheimer's disease 2Neuronal 'traffic jam' marks early Alzheimer's disease 3Neuronal 'traffic jam' marks early Alzheimer's disease 4Poor prenatal nutrition permanently damages function of insulin-producing cells in the pancreas 2Poor prenatal nutrition permanently damages function of insulin-producing cells in the pancreas 3Poor prenatal nutrition permanently damages function of insulin-producing cells in the pancreas 4
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
... protein Vtg in plasma from juvenile or male ... endocrine disrupting chemicals (EDCs) with estrogenic effects in ... screening test for the estrogenic effects of EDCs ... is a double-antibody immunometric (sandwich) EIA for analyzing ...
... is a 17 amino acid synthetic peptide whose sequence is from ... to carboxy terminus): C - N(217) - Q - P ... A - T - P - N - Y - T ... be used for neutralization and control experiments with the polyclonal antibody ...
... for which no antibody exists? Having difficulty generating ... a variety of pharmaceutical, biotech and academic researchers ... technology and expertise in antibody generation to work ... RabMAb development technology , High affinity and high ...
Biology Products: